Use of Botulinum Toxin to Treat Psoriasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00816517|
Recruitment Status : Completed
First Posted : January 1, 2009
Last Update Posted : April 4, 2016
Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoriasis. Botulinum toxin has been shown to have an effect on inhibiting neurogenic inflammation.
Recently, it was reported that patients who suffered from dystonia and had concomitant psoriasis, when treated with botulinum toxin for dystonia noted a dramatic improvement of their psoriatic lesions.
This pilot study will determine the safety and efficacy of botulinum toxin in the management of psoriasis vulgaris.
|Condition or disease||Intervention/treatment||Phase|
|Psoriasis Vulgaris||Biological: injection of botulinum toxin type A.||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pilot Study on the Safety and Efficacy of Botulinum Toxin Injections in the Treatment of Psoriasis Vulgaris.|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||June 2015|
|Actual Study Completion Date :||December 2015|
Experimental: botulinum toxin
injection of botulinum toxin type A
Biological: injection of botulinum toxin type A.
35 to 100 units injected around a skin lesion (plaque) one time.
Other Name: Botox.
- psoriasis scoring scale [ Time Frame: baseline and 3months ]
- 3mm skin biopsy. [ Time Frame: baseline and at 3 months. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00816517
|United States, Minnesota|
|Univerisity of Minnesota|
|Minneapolis, Minnesota, United States, 55444|
|Principal Investigator:||Maria K Hordinsky, MD||University of Minnesota - Clinical and Translational Science Institute|